Fulgent Genetics (FLGT)
Fulgent Genetics on one page: short interest, daily short volume, fails to deliver, planned sales, large holders, 13F holders, financials, earnings dates and insider trades. Listed on Nasdaq, classified by the SEC as services-medical laboratories.
2.2M
Short interest
settlement 2026-09-30
7.2
Days to cover
+0.5 days vs prior
27.1%
Short share of volume
2026-10-12
242
Fails to deliver
settlement 2026-09-14
Fri 6 Nov
Next earnings
estimated date
-$117K
Insider flow, 90 days
0 buys, 4 sells
As of 2026-10-12.
Short interest
FINRA, twice a month. The newest 24 settlements in the table, 48 in the chart. JSONAs of 30 September 2026, short interest in FLGT is 2,238,210 shares, down 130,175 shares over the last month. Over the last 48 readings it ranged from 579,045 shares (15 November 2024) to 2,799,518 shares (29 May 2026). At the reported average volume of 312K shares a day that is 7.2 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/flgt" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-09-30 | 2,238,210 | -3.4% | 311,711 | 7.18 |
| 2026-09-15 | 2,318,058 | -2.1% | 345,550 | 6.71 |
| 2026-08-31 | 2,368,385 | -7.3% | 237,554 | 9.97 |
| 2026-08-14 | 2,555,609 | -0.4% | 274,276 | 9.32 |
| 2026-07-31 | 2,565,192 | -6.8% | 320,516 | 8.00 |
| 2026-07-15 | 2,753,798 | +4.8% | 240,837 | 11.43 |
| 2026-06-30 | 2,627,189 | -3.7% | 332,634 | 7.90 |
| 2026-06-15 | 2,728,242 | -2.5% | 413,008 | 6.61 |
| 2026-05-29 | 2,799,518 | +2.9% | 558,629 | 5.01 |
| 2026-05-15 | 2,719,732 | +8.7% | 695,550 | 3.91 |
| 2026-04-30 | 2,501,018 | -5.9% | 398,151 | 6.28 |
| 2026-04-15 | 2,657,778 | +7.7% | 476,107 | 5.58 |
| 2026-03-31 | 2,467,777 | +15.5% | 753,879 | 3.27 |
| 2026-03-13 | 2,135,898 | +38.6% | 976,923 | 2.19 |
| 2026-02-27 | 1,540,495 | -0.5% | 490,425 | 3.14 |
| 2026-02-13 | 1,547,879 | -8.3% | 224,930 | 6.88 |
| 2026-01-30 | 1,688,422 | +1.4% | 161,645 | 10.45 |
| 2026-01-15 | 1,665,277 | +6.4% | 226,509 | 7.35 |
| 2025-12-31 | 1,565,184 | -11.1% | 192,152 | 8.15 |
| 2025-12-15 | 1,760,997 | -1.6% | 216,697 | 8.13 |
| 2025-11-28 | 1,789,916 | -4.0% | 307,769 | 5.82 |
| 2025-11-14 | 1,865,563 | -0.5% | 501,213 | 3.72 |
| 2025-10-31 | 1,874,917 | -1.9% | 209,422 | 8.95 |
| 2025-10-15 | 1,911,083 | -1.4% | 188,422 | 10.14 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 12 October 2026, the short share of FLGT volume is 27.1%, down 30.2 points over the last five sessions. Over the last 30 readings it ranged from 27.1% (12 October 2026) to 66.8% (1 October 2026). The latest reading sits at the bottom of that range. The latest reading is 20.5 points below the 30-session average of 47.6%, on 101K shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-10-12 | 27K | 101K | 27.1% | 0 |
| 2026-10-09 | 36K | 89K | 39.9% | 0 |
| 2026-10-08 | 72K | 147K | 48.6% | 0 |
| 2026-10-07 | 37K | 72K | 51.6% | 0 |
| 2026-10-06 | 75K | 135K | 55.5% | 0 |
| 2026-10-05 | 56K | 99K | 57.2% | 220 |
| 2026-10-02 | 64K | 104K | 61.7% | 0 |
| 2026-10-01 | 67K | 100K | 66.8% | 0 |
| 2026-09-30 | 39K | 87K | 44.6% | 0 |
| 2026-09-29 | 53K | 82K | 64.4% | 0 |
| 2026-09-28 | 35K | 64K | 54.1% | 322 |
| 2026-09-25 | 38K | 78K | 49.1% | 23 |
| 2026-09-24 | 48K | 83K | 58.0% | 0 |
| 2026-09-23 | 42K | 71K | 59.5% | 19 |
| 2026-09-22 | 37K | 76K | 48.1% | 0 |
| 2026-09-21 | 45K | 131K | 34.4% | 5 |
| 2026-09-18 | 44K | 77K | 56.8% | 836 |
| 2026-09-17 | 55K | 105K | 52.4% | 1 |
| 2026-09-16 | 60K | 130K | 45.8% | 0 |
| 2026-09-15 | 48K | 172K | 27.8% | 53 |
| 2026-09-14 | 54K | 129K | 42.0% | 0 |
| 2026-09-11 | 55K | 125K | 43.9% | 0 |
| 2026-09-10 | 75K | 126K | 59.4% | 0 |
| 2026-09-09 | 91K | 159K | 57.2% | 0 |
| 2026-09-08 | 80K | 168K | 47.9% | 0 |
| 2026-09-04 | 35K | 105K | 33.6% | 0 |
| 2026-09-03 | 47K | 110K | 43.1% | 0 |
| 2026-09-02 | 58K | 182K | 32.1% | 0 |
| 2026-09-01 | 28K | 91K | 31.0% | 0 |
| 2026-08-31 | 39K | 117K | 32.9% | 0 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 14 September 2026, the fails-to-deliver balance in FLGT is 242 shares, up 211 shares over the last settlement date. Over the last 30 readings it ranged from 1 share (11 August 2026) to 10,948 shares (5 May 2026). The latest reading sits at the bottom of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-09-14 | 242 | $20.45 | $5K |
| 2026-09-08 | 31 | $19.73 | $612 |
| 2026-09-02 | 13 | $19.59 | $255 |
| 2026-08-31 | 18 | $19.61 | $353 |
| 2026-08-11 | 1 | $19.06 | $19 |
| 2026-08-04 | 6,200 | $17.61 | $109K |
| 2026-06-30 | 43 | $20.53 | $883 |
| 2026-06-16 | 20 | $18.35 | $367 |
| 2026-06-15 | 1,484 | $18.68 | $28K |
| 2026-06-12 | 452 | $18.78 | $8K |
| 2026-06-03 | 2,336 | $18.70 | $44K |
| 2026-06-02 | 1,057 | $18.09 | $19K |
| 2026-05-29 | 3,623 | $18.24 | $66K |
| 2026-05-28 | 102 | $17.90 | $2K |
| 2026-05-19 | 90 | $15.85 | $1K |
| 2026-05-06 | 3,942 | $14.90 | $59K |
| 2026-05-05 | 10,948 | $15.12 | $166K |
| 2026-04-28 | 3 | $15.60 | $47 |
| 2026-04-13 | 6,429 | $14.43 | $93K |
| 2026-04-08 | 8 | $15.91 | $127 |
| 2026-03-11 | 42 | $14.38 | $604 |
| 2026-02-17 | 344 | $23.43 | $8K |
| 2026-01-27 | 310 | $27.53 | $9K |
| 2025-12-30 | 626 | $26.60 | $17K |
| 2025-11-25 | 236 | $30.65 | $7K |
| 2025-11-12 | 230 | $28.38 | $7K |
| 2025-10-20 | 4,090 | $22.68 | $93K |
| 2025-09-22 | 36 | $22.32 | $804 |
| 2025-08-29 | 3 | $22.03 | $66 |
| 2025-07-30 | 53 | $17.57 | $931 |
Insider trades
SEC Form 4, newest first, 50 of 100 shown. JSONInsiders at FLGT reported 4 open-market sells worth $117K in the last 90 days and no open-market buys. Latest filing: Xie Jian (President and COO) on 2026-09-02.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-09-02 | Xie Jian | President and COO | Sell | 2K | $19.66 | $42K | 360K |
| 2026-09-02 | Gao Hanlin | Chief Scientific Officer | Sell | 2K | $19.66 | $33K | 986K |
| 2026-09-01 | Hsieh Ming | Chief Executive Officer | Tax withholding | 4K | $19.59 | $86K | 886K |
| 2026-09-01 | Kim Paul | CFO and Treasurer | Tax withholding | 2K | $19.59 | $41K | 357K |
| 2026-08-27 | Xie Jian | President and COO | Sell | 1K | $19.91 | $24K | 362K |
| 2026-08-27 | Gao Hanlin | Chief Scientific Officer | Sell | 939 | $19.91 | $19K | 988K |
| 2026-08-26 | Hsieh Ming | Chief Executive Officer | Tax withholding | 3K | $19.81 | $58K | 890K |
| 2026-08-26 | Kim Paul | CFO and Treasurer | Tax withholding | 1K | $19.81 | $23K | 359K |
| 2026-07-26 | Kim Paul | CFO and Treasurer | Tax withholding | 3K | $19.67 | $54K | 360K |
| 2026-07-26 | Xie Jian | President and COO | Tax withholding | 4K | $19.67 | $86K | 363K |
| 2026-07-26 | Gao Hanlin | Chief Scientific Officer | Tax withholding | 2K | $19.67 | $32K | 989K |
| 2026-06-02 | Xie Jian | President and COO | Sell | 2K | $17.89 | $38K | 368K |
| 2026-06-02 | Gao Hanlin | Chief Scientific Officer | Sell | 2K | $17.89 | $30K | 990K |
| 2026-06-01 | Hsieh Ming | Chief Executive Officer | Tax withholding | 4K | $18.09 | $79K | 893K |
| 2026-06-01 | Kim Paul | CFO and Treasurer | Tax withholding | 2K | $18.09 | $38K | 363K |
| 2026-05-27 | Xie Jian | President and COO | Sell | 1K | $17.60 | $21K | 370K |
| 2026-05-27 | Gao Hanlin | Chief Scientific Officer | Sell | 945 | $17.60 | $17K | 992K |
| 2026-05-26 | Hsieh Ming | Chief Executive Officer | Tax withholding | 3K | $17.67 | $52K | 898K |
| 2026-05-26 | Kim Paul | CFO and Treasurer | Tax withholding | 1K | $17.67 | $21K | 365K |
| 2026-05-14 | Nohaile Michael | Director | Grant | 6K | $0.00 | $0 | 25K |
| 2026-05-14 | GROVES REGINA E | Director | Grant | 11K | $0.00 | $0 | 28K |
| 2026-05-14 | Dong Linda | Director | Grant | 11K | $0.00 | $0 | 39K |
| 2026-04-26 | Gao Hanlin | Chief Scientific Officer | Tax withholding | 2K | $16.31 | $27K | 993K |
| 2026-04-26 | Xie Jian | President and COO | Tax withholding | 4K | $16.31 | $71K | 371K |
| 2026-04-26 | Kim Paul | CFO and Treasurer | Tax withholding | 3K | $16.31 | $45K | 366K |
| 2026-03-01 | Xie Jian | President and COO | Tax withholding | 8K | $15.33 | $125K | 375K |
| 2026-03-01 | Xie Jian | President and COO | Tax withholding | 1K | $15.33 | $17K | 383K |
| 2026-03-01 | Gao Hanlin | Chief Scientific Officer | Tax withholding | 6K | $15.33 | $98K | 995K |
| 2026-03-01 | Gao Hanlin | Chief Scientific Officer | Tax withholding | 1K | $15.33 | $16K | 1.0M |
| 2026-03-01 | Hsieh Ming | Chief Executive Officer | Tax withholding | 18K | $15.33 | $269K | 901K |
| 2026-03-01 | Kim Paul | CFO and Treasurer | Tax withholding | 8K | $15.33 | $128K | 369K |
| 2026-03-01 | Kim Paul | CFO and Treasurer | Tax withholding | 1K | $15.33 | $17K | 377K |
| 2026-02-26 | Xie Jian | President and COO | Tax withholding | 1K | $24.76 | $28K | 385K |
| 2026-02-26 | Gao Hanlin | Chief Scientific Officer | Tax withholding | 897 | $24.76 | $22K | 1.0M |
| 2026-02-26 | Hsieh Ming | Chief Executive Officer | Tax withholding | 3K | $24.76 | $73K | 918K |
| 2026-02-26 | Kim Paul | CFO and Treasurer | Tax withholding | 1K | $24.76 | $29K | 378K |
| 2026-02-24 | Kim Paul | CFO and Treasurer | Grant | 31K | $0.00 | $0 | 379K |
| 2026-02-24 | Kim Paul | CFO and Treasurer | Tax withholding | 15K | $23.09 | $349K | 348K |
| 2026-02-24 | Kim Paul | CFO and Treasurer | Tax withholding | 8K | $23.09 | $195K | 363K |
| 2026-02-24 | Kim Paul | CFO and Treasurer | Tax withholding | 3K | $23.09 | $75K | 372K |
| 2026-02-24 | Kim Paul | CFO and Treasurer | Grant | 27K | $0.00 | $0 | 375K |
| 2026-02-24 | Kim Paul | CFO and Treasurer | Grant | 15K | $0.00 | $0 | 348K |
| 2026-02-24 | Kim Paul | CFO and Treasurer | Grant | 6K | $0.00 | $0 | 333K |
| 2026-02-24 | Xie Jian | President and COO | Grant | 32K | $0.00 | $0 | 386K |
| 2026-02-24 | Xie Jian | President and COO | Tax withholding | 15K | $23.09 | $341K | 354K |
| 2026-02-24 | Xie Jian | President and COO | Tax withholding | 8K | $23.09 | $191K | 368K |
| 2026-02-24 | Xie Jian | President and COO | Tax withholding | 3K | $23.09 | $73K | 377K |
| 2026-02-24 | Xie Jian | President and COO | Grant | 27K | $0.00 | $0 | 380K |
| 2026-02-24 | Xie Jian | President and COO | Grant | 15K | $0.00 | $0 | 353K |
| 2026-02-24 | Xie Jian | President and COO | Grant | 6K | $0.00 | $0 | 337K |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Planned sales (Form 144)
Newest first. JSON12 Form 144 notices on file for FLGT worth $611K at the prices reported; 4 in the last 90 days worth $117K. Latest: Xie Jian filed on 2026-09-02 to sell 2,127 shares ($42K) from 2026-09-02.
| Filed | Seller | Shares | Market value | Of outstanding | Sale from | Broker |
|---|---|---|---|---|---|---|
| 2026-09-02 | Xie JianOfficer | 2K | $42K | 0.008% | 2026-09-02 | Morgan Stanley Smith Barney LLC |
| 2026-09-02 | Gao HanlinOfficer | 2K | $33K | 0.006% | 2026-09-02 | Morgan Stanley Smith Barney LLC |
| 2026-08-27 | Xie JianOfficer | 1K | $24K | 0.004% | 2026-08-27 | Morgan Stanley Smith Barney LLC |
| 2026-08-27 | Gao HanlinOfficer | 939 | $19K | 0.003% | 2026-08-27 | Morgan Stanley Smith Barney LLC |
| 2026-06-02 | Xie JianOfficer | 2K | $38K | 0.008% | 2026-06-02 | Morgan Stanley Smith Barney LLC |
| 2025-12-01 | Gao HanlinOfficer | 1K | $31K | 0.003% | 2025-12-02 | Morgan Stanley Smith Barney LLC |
| 2025-12-01 | Xie JianOfficer | 1K | $32K | 0.004% | 2025-12-02 | Morgan Stanley Smith Barney LLC |
| 2025-11-26 | Xie JianOfficer | 1K | $36K | 0.004% | 2025-11-28 | Morgan Stanley Smith Barney LLC |
| 2025-11-26 | Gao HanlinOfficer | 943 | $28K | 0.003% | 2025-11-28 | Morgan Stanley Smith Barney LLC |
| 2025-11-24 | Xie JianOfficer | 681 | $21K | 0.002% | 2025-11-24 | Morgan Stanley Smith Barney LLC |
| 2025-11-24 | Gao HanlinOfficer | 535 | $16K | 0.002% | 2025-11-24 | Morgan Stanley Smith Barney LLC |
| 2025-11-19 | Xie JianOfficer | 10K | $291K | 0.032% | 2025-11-19 | Raymond James & Associates |
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first. JSON2 holders report 5% or more of FLGT in their latest filing, all on Schedule 13D (active intent). The largest reported stake is Ming Hsieh at 32.3% of the class (8,872,539 shares), filed 2026-05-27 for an event on 2026-05-22.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-05-27 | 13D/Ano. 5 | Ming Hsiehindividual | 8.9M | 32.3% | 2026-05-22 |
| 2026-05-27 | 13D/Ano. 5 | The Ming Hsieh Trustother entity | 7.9M | 28.7% | 2026-05-22 |
| 2026-02-04 | 13G/Ano. 4 | Israel A. Englanderindividual | 939K | 3.0% | 2025-12-31 |
| 2026-02-04 | 13G/Ano. 4 | Integrated Core Strategies (US) LLCother entity | 919K | 3.0% | 2025-12-31 |
| 2026-02-04 | 13G/Ano. 4 | Millennium Management LLCother entity | 939K | 3.0% | 2025-12-31 |
| 2026-02-04 | 13G/Ano. 4 | Millennium Group Management LLCother entity | 939K | 3.0% | 2025-12-31 |
13F holders
Tracked managers holding FLGT at their latest 13F. JSON6 of the 30 tracked managers held FLGT at their latest 13F, $30.1M in total at quarter-end prices. Two Sigma Investments is the largest at $8.2M (0.0% of its portfolio) as of 2026-06-30. Over the prior quarter 4 added shares and 2 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| Two Sigma Investments | 2026-06-30 | 401K | $8.2M | 0.01% | +79K |
| Millennium Management | 2026-06-30 | 321K | $6.6M | 0.00% | -81K |
| D. E. Shaw & Co. | 2026-06-30 | 292K | $6.0M | 0.00% | -195K |
| Point72 Asset Management | 2026-06-30 | 212K | $4.3M | 0.00% | new |
| Citadel Advisors | 2026-06-30 | 174K | $3.6M | 0.00% | +121K |
| AQR Capital Management | 2026-06-30 | 69K | $1.4M | 0.00% | +40K |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
Financials
SEC XBRL, as filed. JSONIn Q2 FY 2026 (quarter ended 2026-06-30) Fulgent Genetics reported revenue of $85.4M, up 4.4% from the same quarter a year earlier, and net loss of $29.5M. In FY 2025 it generated -$101.6M of operating cash flow and spent $10.9M on buybacks.
- Cash
- $26.3M
- Equity
- $1.00B
- Total assets
- $1.09B
- Shares outstanding
- 27,515,293
Quarterly, last 8 quarters
| Quarter | Period end | Revenue | Net income | Margin | Diluted EPS |
|---|---|---|---|---|---|
| Q2 FY 2026 | 2026-06-30 | $85.4M | -$29.5M | -34.6% | n/a |
| Q1 FY 2026 | 2026-03-31 | $71.1M | -$24.8M | -34.9% | n/a |
| Q4 FY 2025derived | 2025-12-31 | $83.3M | -$23.4M | -28.1% | n/a |
| Q3 FY 2025 | 2025-09-30 | $84.1M | -$6.6M | -7.9% | n/a |
| Q2 FY 2025 | 2025-06-30 | $81.8M | -$19.0M | -23.2% | n/a |
| Q1 FY 2025 | 2025-03-31 | $73.5M | -$11.5M | -15.7% | n/a |
| Q4 FY 2024derived | 2024-12-31 | $76.2M | -$5.9M | -7.7% | n/a |
| Q3 FY 2024 | 2024-09-30 | $71.7M | -$14.6M | -20.4% | n/a |
Fiscal years, with buybacks and dividends
| Fiscal year | Ends | Revenue | Net income | Operating cash flow | Capex | Buybacks | Dividends |
|---|---|---|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $322.7M | -$60.5M | -$101.6M | $22.6M | $10.9M | n/a |
| FY 2024 | 2024-12-31 | $283.5M | -$42.7M | $21.1M | $40.3M | $225K | n/a |
| FY 2023 | 2023-12-31 | $289.2M | -$167.8M | $27.0M | $22.2M | $25.1M | n/a |
| FY 2022 | 2022-12-31 | $619.0M | $143.4M | $253.5M | $18.8M | $74.3M | n/a |
| FY 2021 | 2021-12-31 | $992.6M | $507.4M | $538.6M | $23.8M | n/a | n/a |
Quarters are the three-month figures the company reports; a fourth quarter marked derived is the fiscal year less the three reported quarters, since companies report it only inside the 10-K. Fiscal years are the annual figures. Buybacks are the cash the company paid to repurchase its common stock in the year, not the amount authorized. Balance sheet lines are as of 2026-06-30; shares outstanding as of 2026-07-27 from the cover page.
What this page is
Fulgent Genetics in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows Fulgent Genetics (FLGT), SEC CIK 1674930, listed on Nasdaq, classified by the SEC as services-medical laboratories. The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-09-30.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-10-12.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-09-14.JSON and CSV
- Planned sales
- SEC EDGAR Form 144Source: SEC.New notices appear shortly after the SEC posts them; a notice is filed on or before the sale. Latest 2026-09-02.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-05-27.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Financials
- SEC EDGAR 10-K and 10-Q filingsSource: SEC.Weekly; values are as filed in the 10-Q and 10-K. Latest 2026-06-30.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-07-30.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-09-02.JSON and CSV
- Company record
- EDGAR filing index for CIK 1674930Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as services-medical laboratories
Other company pages
Datasets
Frequently Asked Questions
How much of FLGT is sold short?
What is FLGT's daily short volume?
Does FLGT have fails to deliver?
Are FLGT insiders buying or selling?
Have FLGT insiders filed to sell?
Who owns 5% or more of FLGT?
What did FLGT report last quarter?
Which tracked 13F managers own FLGT?
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.